Multiple Immunotherapies Fail to Show Durable Survival on ASCO Value Framework

Source: Healio, December 2017

Only two of 23 indications for six FDA-approved immuno-oncology agents showed durable survival benefits under the revised ASCO value framework, according to study findings.

“There are [two] possible reasons for this,” Omer Ben-Aharon, MBA, MHA, from the department of management and health system management program at Bar-Ilan University in Israel, and colleagues wrote. “The first is that the public excitement concerning durable survival with immuno-oncology may lack sufficient supporting data. The second is that the ASCO value framework may be insufficiently calibrated to reward durable survival benefits.”

ASCO developed a conceptual framework to measure the value of cancer treatment options.

read the original full article

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories